Ghost Tree Capital’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Ghost Tree Capital’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-350,000	Closed	-$8.02M	–	64
2018 Q1	$8.02M	Buy	+350,000	New	+$7.78M	1.62%	20
2014 Q4	–	Sell	-280,966	Closed	-$3.54M	–	85
2014 Q3	$3.54M	Buy	+280,966	New	+$2.73M	1.92%	22

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ghost Tree Capital's CNCE Position: Q2 2018 in Review

Ghost Tree Capital sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2018, closing a stake of 350,000 shares — an estimated $8.02M sold.

Ghost Tree Capital first reported a position in CNCE in Q3 2014 and held it in 2 quarters. The position peaked at $8.02M in Q1 2018. 120 funds tracked by Wall St. Rank hold CNCE as of Q2 2018.

Ghost Tree Capital reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Ghost Tree Capital sold 350,000 Concert Pharmaceuticals, Inc. shares in Q2 2018, an estimated $8.02M.
Ghost Tree Capital first reported a position in Concert Pharmaceuticals, Inc. in Q3 2014 and held it in 2 quarters.
Ghost Tree Capital's Concert Pharmaceuticals, Inc. position peaked at $8.02M in Q1 2018.
120 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2018.

Based on Ghost Tree Capital's 13F filing for Q2 2018, filed 14 Aug 2018.